Artículo

Production of monoclonal antibodies in microfluidic devices

Bourguignon, Natalia Icon; Attallah, Carolina Veronica Icon; Karp, Paola Julieta Icon; Booth, Ross ; Peñaherrera Pazmiño, Ana Belén Icon; Payés, Cristian Icon; Oggero Eberhardt, Marcos Rafael Icon; Perez, Maximiliano Sebastian Icon; Helguera, Gustavo Fernando Icon; Lerner, Betiana Icon

Otros responsables

Fecha

03/2018

Editorial

Royal Society of Chemistry

Revista

Integrative Biology

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

1757-9694

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Herein, a microfluidic device with cistern design for cultivation of adherent eukaryotic cells for the production of recombinant proteins is presented. The geometric configuration of the microchannels in the device provided laminar flow with reduced velocity profiles in the cisterns, resulting in an adequate microenvironment for long-term adherent cell growth with passive pumping flow cycles of 24 hours. CHO-ahIFNα2b and HEK-ahIFNα2b adherent cell lines expressing a novel anti-hIFN-α2b recombinant monoclonal antibody (MAb) for the treatment of systemic lupus erythematosus were cultured on the surface of PDMS/glass microchannels coated with poly-d-lysine. A 24 day culture of CHO-ahIFNα2b cells resulted in MAb concentrations up to 166.4 μg mL -1 per day. The productivity of CHO-ahIFNα2b and HEK-ahIFNα2b cell lines was higher in the microdevice compared to that obtained using the adherent cell culture method (T-flask), with a 5.89- and 7.31-fold increase, respectively. Moreover, biological analysis of the MAbs produced in the microdevice showed no significant differences in the neutralizing antiproliferative activity of the hIFN-α2b or the cytokine cell signaling compared to the MAbs produced with cell adherent methods. These results suggest that this microfluidic device is suitable for long-term culture of mammalian cells and can improve the productivity of cells expressing recombinant MAbs with potential for therapeutic use without affecting the quality attributes of the product.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa